Related Experiment Videos
[The role of the granulocytes in ischemic cardiopathy]
A Mazzone1, D Pasotti, I Mazzucchelli
1Dipartimento di Medicina Interna e Terapia Medica, Università, IRCCS Policlinico San Matteo, Pavia.
Abstract:
Recent studies suggest that granulocytes (PMNs) play a role in the pathogenesis of acute and chronic myocardial ischemia and extension of myocardial injury. Granulocytes can release a variety of mediators tissue injury and synergize with these different mediators, cytokines and other cells resulting in amplification of neutrophil stimulation and rising to additional products with enhanced endothelial injury. Free radicals released by PMNs during ischemia or reperfusion produce deleterious effects on cell membranes, endothelial cells and myocardium. Experience in humans shows the modification of PMNs function in angina and during myocardial ischemia: upon reperfusion PMNs accumulate and produce an inflammatory response leading to endothelial injury. Rabbit derived antiserum dependent-reduction of circulating PMNs in the dog or using monoclonal antibody anti-CD11b/CD18 of PMNs resulted in smaller myocardial infarction. Another aspect of PMNs function is related to leukotriene C4 release; the vasoconstrictor effect of this leukotriene on coronary arteries is synergistic with that induced by platelet-released thromboxane A2, and the decrease in coronary flow produced by the combination of both substances is greater than the sum of changes caused by the two eicosanoids separately administered. The potential role of leukocytes, oxygen radicals, leukotrienes and granulocyte enzymes in the pathophysiology of myocardial injury due to regional ischemia and reperfusion is an area of intense investigation. This overview will not attempt to be exhaustive. Experimental and clinical studies to elucidate these events should not only provide insight into acute and chronic pathologic tissue damage, but may also lead to the identification of important new targets of pharmacologic intervention.
Insights
Polymorphonuclear neutrophils (PMNs) contribute to myocardial ischemia and injury by releasing harmful mediators and free radicals. Reducing PMN activity can limit heart damage and offers potential therapeutic targets.
Area of Science:
- Cardiovascular Pathophysiology
- Inflammatory Medicine
- Myocardial Ischemia Research
Context:
- Recent studies highlight the significant role of granulocytes, specifically polymorphonuclear neutrophils (PMNs), in the development and progression of myocardial ischemia.
- PMNs contribute to tissue damage through the release of various mediators, cytokines, and free radicals, amplifying inflammatory responses and endothelial injury.
Purpose:
- To review the multifaceted role of PMNs in myocardial ischemia and reperfusion injury.
- To explore the mechanisms by which PMNs exacerbate myocardial damage, including mediator release and synergistic effects.
- To discuss potential therapeutic strategies targeting PMN function for managing ischemic heart disease.
Summary:
- PMNs release mediators and free radicals that cause direct myocardial and endothelial injury during ischemia and reperfusion.
- Experimental interventions reducing PMN levels or activity, such as using anti-CD11b/CD18 antibodies, have shown a reduction in myocardial infarction size.
- Leukotriene C4 released by PMNs has synergistic vasoconstrictive effects with thromboxane A2, further impairing coronary blood flow.
Impact:
- Understanding PMN involvement in myocardial injury provides critical insights into acute and chronic tissue damage mechanisms.
- Identifying PMN-related pathways offers potential new targets for pharmacologic interventions aimed at limiting myocardial infarction and improving patient outcomes.